Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
BridgeBio Pharma’s Formation of GondolaBio
Skadden is advising BridgeBio Pharma, Inc. on the deal, while Goodwin Procter LLP and Richards, Layton & Finger P.A. are acting as legal advisors to the...
BridgeBio Pharma’s Partnership with Kyowa Kirin
Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
BridgeBio’s $110 Million Sale of Priority Review Voucher
Goodwin Procter advised BridgeBio on the deal. BridgeBio announced its definitive agreement with an undisclosed purchaser to sell its rare pediatric disease Priority Review Voucher for $110...
BridgeBio Pharma’s License Agreement with Bristol Myers Squibb
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
BridgeBio Pharma’s Credit Facility Amendment
Latham & Watkins advised BridgeBio on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into...
BridgeBio Pharma’s $750 Million Non-Dilutive Debt Financing
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
BridgeBio Pharma’s $2.45 Billion Collaboration and Licensing Agreement with Helsinn Group
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...